A multi-centre trial comparing a sulfamethopyrazine/trimethoprim combination with co-trimoxazole in respiratory tract infections

M. L. Colombo, V. Peona, F. Ginesu, A. R. Ortu, A. Bagnato, D. Dei, F. Colombo, L. Donno

Research output: Contribution to journalArticle

Abstract

A double-blind, multi-centre trial was carried out in 72 patients with acute or chronic infections of the lower respiratory tract to compare the efficacy and tolerance of a sulfamethopyrazine (200 mg)/trimethoprim (250 mg) combination with that of the established combination cotrimoxazole (400 mg sulphamethoxazole plus 80 mg trimethoprim). Patients received treatment for 10 days either with 2 capsules of co-trimoxazole twice daily or in the newer combination group, with 2 capsules on Day 1 and then 1 capsule daily for the remainder of the treatment period. The results of clinical, bacteriological and functional tests showed an excellent or good response in over 90% of patients in each group. There was no statistically significant difference in effectiveness of treatment with the once-daily sulfamethopyrazine/trimethoprim regimen compared with co-trimoxazole given twice daily. Both treatments were well tolerated, with only a few mild side-effects, mainly gastro-intestinal ones, being reported.

Original languageEnglish
Pages (from-to)556
Number of pages1
JournalPharmatherapeutica
Volume3
Issue number8
Publication statusPublished - 1984

Fingerprint

Sulfalene
Trimethoprim
Sulfamethoxazole Drug Combination Trimethoprim
Respiratory Tract Infections
Capsules
Sulfamethoxazole
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Colombo, M. L., Peona, V., Ginesu, F., Ortu, A. R., Bagnato, A., Dei, D., ... Donno, L. (1984). A multi-centre trial comparing a sulfamethopyrazine/trimethoprim combination with co-trimoxazole in respiratory tract infections. Pharmatherapeutica, 3(8), 556.

A multi-centre trial comparing a sulfamethopyrazine/trimethoprim combination with co-trimoxazole in respiratory tract infections. / Colombo, M. L.; Peona, V.; Ginesu, F.; Ortu, A. R.; Bagnato, A.; Dei, D.; Colombo, F.; Donno, L.

In: Pharmatherapeutica, Vol. 3, No. 8, 1984, p. 556.

Research output: Contribution to journalArticle

Colombo, ML, Peona, V, Ginesu, F, Ortu, AR, Bagnato, A, Dei, D, Colombo, F & Donno, L 1984, 'A multi-centre trial comparing a sulfamethopyrazine/trimethoprim combination with co-trimoxazole in respiratory tract infections', Pharmatherapeutica, vol. 3, no. 8, pp. 556.
Colombo, M. L. ; Peona, V. ; Ginesu, F. ; Ortu, A. R. ; Bagnato, A. ; Dei, D. ; Colombo, F. ; Donno, L. / A multi-centre trial comparing a sulfamethopyrazine/trimethoprim combination with co-trimoxazole in respiratory tract infections. In: Pharmatherapeutica. 1984 ; Vol. 3, No. 8. pp. 556.
@article{5f54a9bf4d3a473e9d964d6acb09bf08,
title = "A multi-centre trial comparing a sulfamethopyrazine/trimethoprim combination with co-trimoxazole in respiratory tract infections",
abstract = "A double-blind, multi-centre trial was carried out in 72 patients with acute or chronic infections of the lower respiratory tract to compare the efficacy and tolerance of a sulfamethopyrazine (200 mg)/trimethoprim (250 mg) combination with that of the established combination cotrimoxazole (400 mg sulphamethoxazole plus 80 mg trimethoprim). Patients received treatment for 10 days either with 2 capsules of co-trimoxazole twice daily or in the newer combination group, with 2 capsules on Day 1 and then 1 capsule daily for the remainder of the treatment period. The results of clinical, bacteriological and functional tests showed an excellent or good response in over 90{\%} of patients in each group. There was no statistically significant difference in effectiveness of treatment with the once-daily sulfamethopyrazine/trimethoprim regimen compared with co-trimoxazole given twice daily. Both treatments were well tolerated, with only a few mild side-effects, mainly gastro-intestinal ones, being reported.",
author = "Colombo, {M. L.} and V. Peona and F. Ginesu and Ortu, {A. R.} and A. Bagnato and D. Dei and F. Colombo and L. Donno",
year = "1984",
language = "English",
volume = "3",
pages = "556",
journal = "Pharmatherapeutica",
issn = "0308-051X",
number = "8",

}

TY - JOUR

T1 - A multi-centre trial comparing a sulfamethopyrazine/trimethoprim combination with co-trimoxazole in respiratory tract infections

AU - Colombo, M. L.

AU - Peona, V.

AU - Ginesu, F.

AU - Ortu, A. R.

AU - Bagnato, A.

AU - Dei, D.

AU - Colombo, F.

AU - Donno, L.

PY - 1984

Y1 - 1984

N2 - A double-blind, multi-centre trial was carried out in 72 patients with acute or chronic infections of the lower respiratory tract to compare the efficacy and tolerance of a sulfamethopyrazine (200 mg)/trimethoprim (250 mg) combination with that of the established combination cotrimoxazole (400 mg sulphamethoxazole plus 80 mg trimethoprim). Patients received treatment for 10 days either with 2 capsules of co-trimoxazole twice daily or in the newer combination group, with 2 capsules on Day 1 and then 1 capsule daily for the remainder of the treatment period. The results of clinical, bacteriological and functional tests showed an excellent or good response in over 90% of patients in each group. There was no statistically significant difference in effectiveness of treatment with the once-daily sulfamethopyrazine/trimethoprim regimen compared with co-trimoxazole given twice daily. Both treatments were well tolerated, with only a few mild side-effects, mainly gastro-intestinal ones, being reported.

AB - A double-blind, multi-centre trial was carried out in 72 patients with acute or chronic infections of the lower respiratory tract to compare the efficacy and tolerance of a sulfamethopyrazine (200 mg)/trimethoprim (250 mg) combination with that of the established combination cotrimoxazole (400 mg sulphamethoxazole plus 80 mg trimethoprim). Patients received treatment for 10 days either with 2 capsules of co-trimoxazole twice daily or in the newer combination group, with 2 capsules on Day 1 and then 1 capsule daily for the remainder of the treatment period. The results of clinical, bacteriological and functional tests showed an excellent or good response in over 90% of patients in each group. There was no statistically significant difference in effectiveness of treatment with the once-daily sulfamethopyrazine/trimethoprim regimen compared with co-trimoxazole given twice daily. Both treatments were well tolerated, with only a few mild side-effects, mainly gastro-intestinal ones, being reported.

UR - http://www.scopus.com/inward/record.url?scp=0021350783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021350783&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 556

JO - Pharmatherapeutica

JF - Pharmatherapeutica

SN - 0308-051X

IS - 8

ER -